Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 4
Submit an article Journal homepage
2,599
Views
9
CrossRef citations to date
0
Altmetric
Editorial

Tracking the price of existing biologics when drugs enter the market

Katherine M. StiffCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
,
Abigail ClineCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4464-4727
ORCID Icon &
Steven R. FeldmanCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA;Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA;Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA;Department of Dermatology, University of Southern Denmark, Odense, DenmarkORCID Iconhttps://orcid.org/0000-0002-0090-6289
ORCID Icon
Pages 375-377 | Received 21 May 2019, Accepted 07 Jun 2019, Published online: 12 Jun 2019

References

  • Aitken M, Kleinrock M. Medicine use and spending in the U.S.: a review of 2017 and outlook to 2022. IQVIA Institute. 2018.
  • Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2016;7(1):97–109. PubMed PMID: 27905011; eng.
  • San-Juan-Rodriguez A, Prokopovich MV, Shrank WH, et al. Assessment of price changes of existing tumor necrosis factor inhibitors after the market entry of competitorschanges in the prices of existing TNF Inhibitors after the market entry of competitorsLetters. JAMA Intern Med. 2019;179(5):713–716. .
  • Cline A, Turrentine JE. Biomedical and market issues surrounding the advent of biosimilars. Dermatol Ther (Heidelb). 2016;6:341–345.
  • Administration UFaD. Guidance for industry: biosimilars: additional questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Food and Drug Administration. 2015.
  • Administration USFaD. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Food and Drug Administration. 2015.
  • Pfizer announces the U.S. availability of biosimilar INFLECTRA® (infliximab-dyyb). 2016. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_the_u_s_availability_of_biosimilar_inflectra_infliximab_dyyb
  • Atteberry P, Bach PB, Ohn JA, et al. Biologics are natural monopolies (Part 1): why biosimilars do not create effective competition. Health Affairs Blog. 2019. DOI:10.1377/hblog20190405.396631
  • Yu B. Greater potential cost savings with biosimilar use. Am J Manag Care. 2016 May;22(5):378. PubMed PMID: 27266439; eng.
  • Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018 Mar;7(4):3. PubMed PMID: 30083415; PubMed Central PMCID: PMCPMC6075809. eng.
  • Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: an overview. PloS One. 2017;12(12):e0190147–e0190147. PubMed PMID: 29284064; eng.
  • Huge discount on biosimilar infliximab in Norway [Internet]. Mol, Belgium: GaBI Online. 2015 [cited 2019 May 20]. Available from: www.gabionline.net
  • Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013 Sep-Oct;6(8):469–478. PubMed PMID: PMC4031732.
  • Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017 Jan;33(12):2160–2172. PubMed PMID: 27798772; PubMed Central PMCID: PMCPMC5126187. eng.
  • Cline A, Hill D, Lewallen R, et al. Current status and future prospects for biologic treatments of psoriasis. Expert Rev Clin Immunol. 2016 Jul 6:1–15. PubMed PMID: 27327580; Eng. DOI:10.1080/1744666x.2016.1202115
  • Feldman SR. Biomedical and market issues surrounding the advent of biosimilars. Expert Rev Clin Immunol. 2016 Sep;6(3):341–345. PubMed PMID: 27329376; eng. .
  • Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070. PubMed PMID: 30294275; eng. DOI:10.3389/fphar.2018.01070.
  • HHS finalizes rule requiring manufacturers disclose drug prices in TV ads to increase drug pricing transparency [Internet]. U.S. Department of Health & Human Services. 2019 May 8. Available from: https://www.hhs.gov/about/news/2019/05/08/hhs-finalizes-rule-requiring-manufacturers-disclose-drug-prices-in-tv-ads.html

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.